Posted on
Share on Facebook
Share on Twitter
Share on LinkedIn

The US Food and Drug Administration has ordered GlaxoSmithKline to review its manufacturing operations globally after finding that its Canadian subsidiary violated quality requirements during the manufacture of its flu vaccine FluLaval.

Click here to read more.